University of Florida Researchers have developed a system designed to identify patients at high risk of discontinuing buprenorphine treatment due to opioid use disorder.
Buprenorphine, an FDA-approved prescription drug, is one of three over-the-counter treatments for opioid use disorder that have proven effective in treating both pain and addiction.
in The study was published in the journal Computers in Biology and Medicine. Dr. Mahmudul Hasan, His research team found that approximately 15% of patients did not complete the clinically recommended 1 year of buprenorphine treatment, and approximately 46% of patients discontinued treatment within the first 3 months. did. With the help of artificial intelligence (AI), the team also identified several factors associated with high-risk patients and treatment discontinuation.
Assistant Professor Hassan University of Florida College of Pharmacy Department of Pharmaceutical Outcomes and Policy By joint appointment in The Department of Information Systems and Operations Management at the University of Florida's Warrington College of Commerce conducted this retrospective study of insured individuals ages 18 to 64 who were prescribed buprenorphine to treat opioid use disorder. It said it would provide new insights that could help fight the epidemic. More than 80,000 lives were lost in the United States in 2021.
read more …
May 16, 2024
